• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Robin M. Joyce, MD

Publications

  • Tzachanis D, Hamdan A, Uhlmann EJ, Joyce RM.Successful Treatment of Refractory Guillain-BarrĂ© Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia.Acta Haematol. 2014 May 17;132(2):240-243.
    24853856
  • Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D.MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.Cancer Res. 2013 Sep 1;73(17):5569-79.
    23867470
  • Warner JL, Alterovitz G, Bodio K, Joyce RM.External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma.J Am Med Inform Assoc. 2013 Apr 13.
    23515788
  • Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J.Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.Haematologica. 2012 Nov 9.
    23144193
  • Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D.Lenalidomide enhances anti-myeloma cellular immunity.Cancer Immunol Immunother. 2012 Jun 24.
    22733396
  • Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.Blood. 2011 Jan 13;117(2):393-402.
    21030562
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
    20385792
  • Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.J Immunother.;33(2):155-66.
    20145548
  • Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD.Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.Cancer. 2010 Jan 1;116(1):106-14.
    19890959
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.British Journal of Haematology. 2009 Jun;145(6):741-8.
    19344412
  • Siddiqi T,Joyce RM.A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.Clin Lymphoma Myeloma. 2008 Oct;8(5):300-4.
    18854285
  • Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A.Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248.Clin Cancer Res. 2007 Jun 1;13(11):3320-5.
    17545538
  • Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC.Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2005 Mar;11(3):213-22.
    15744240
  • Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D.A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).Ann Oncol. 2003;14 Suppl 1:i21-7.
    12736227
  • Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E.The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe.Biol Blood Marrow Transplant. 2002;8(4):198-205.
    12017145
  • Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP.A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses.J Immunol. 2001 Nov 15;167(10):5531-4.
    11698421
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.Bone Marrow Transplant. 2001 Sep;28(5):447-54.
    11593317
  • Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D.Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.Eur J Haematol Suppl. 2001 Jul(64):56-62.
    11486404
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.Bone Marrow Transplant. 2001 Feb;27(3):269-78.
    11277174
  • Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D.Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoin.Clin Cancer Res. 1999 Oct;5(10):2735-41.
    10537336